AlzeCure Pharma (ALZCUR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AlzeCure Pharma (ALZCUR) has a cash flow conversion efficiency ratio of -0.150x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.62 Million ≈ $-819.93K USD) by net assets (Skr50.66 Million ≈ $5.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ALZCUR defensive interval ratio to measure how many days the company can operate on defensive assets alone.
AlzeCure Pharma - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how AlzeCure Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AlzeCure Pharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AlzeCure Pharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rompetrol Well
RO:PTR
|
0.020x |
|
Jourdeness Group Ltd
TW:4190
|
0.101x |
|
SKB Shutters Corporation Bhd
KLSE:7115
|
-0.003x |
|
Southern Rubber Industry JSC
VN:CSM
|
0.143x |
|
Kolon Industries Inc
KO:120115
|
0.031x |
|
Rockhaven Resources Ltd
V:RK
|
-0.001x |
|
Hong Yi Fiber Industry Co Ltd
TW:1452
|
-0.021x |
|
Lexibook Linguistic Electronic System SA
PA:ALLEX
|
-0.217x |
Annual Cash Flow Conversion Efficiency for AlzeCure Pharma (2017–2024)
The table below shows the annual cash flow conversion efficiency of AlzeCure Pharma from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of AlzeCure Pharma.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr26.18 Million ≈ $2.82 Million |
Skr-35.12 Million ≈ $-3.78 Million |
-1.341x | -1143.15% |
| 2023-12-31 | Skr23.77 Million ≈ $2.56 Million |
Skr3.06 Million ≈ $328.98K |
0.129x | +107.78% |
| 2022-12-31 | Skr60.48 Million ≈ $6.51 Million |
Skr-99.91 Million ≈ $-10.75 Million |
-1.652x | +22.89% |
| 2021-12-31 | Skr32.97 Million ≈ $3.55 Million |
Skr-70.64 Million ≈ $-7.60 Million |
-2.142x | -241.35% |
| 2020-12-31 | Skr110.75 Million ≈ $11.92 Million |
Skr-69.51 Million ≈ $-7.48 Million |
-0.628x | -127.15% |
| 2019-12-31 | Skr182.01 Million ≈ $19.59 Million |
Skr-50.28 Million ≈ $-5.41 Million |
-0.276x | -77.59% |
| 2018-12-31 | Skr233.17 Million ≈ $25.09 Million |
Skr-36.27 Million ≈ $-3.90 Million |
-0.156x | +4.26% |
| 2017-12-31 | Skr51.83 Million ≈ $5.58 Million |
Skr-8.42 Million ≈ $-906.23K |
-0.162x | -- |
About AlzeCure Pharma
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sl… Read more